Allergy Therapeutics (LON:AGY) Issues Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) released its earnings results on Monday. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%.

Allergy Therapeutics Price Performance

LON AGY traded down GBX 0.60 ($0.01) during trading hours on Wednesday, hitting GBX 5.85 ($0.08). 451,067 shares of the company’s stock traded hands, compared to its average volume of 391,161. The company has a market capitalization of £287.53 million, a PE ratio of -5.64, a PEG ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48. Allergy Therapeutics has a 52-week low of GBX 2.65 ($0.03) and a 52-week high of GBX 8 ($0.10). The firm’s 50-day moving average is GBX 6.57 and its 200-day moving average is GBX 5.92.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.